

# Suresh Senan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9093829/suresh-senan-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

377  
papers

20,855  
citations

76  
h-index

135  
g-index

398  
ext. papers

25,069  
ext. citations

3.5  
avg, IF

6.71  
L-index

#	Paper	IF	Citations
377	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101308	2.2	42
376	Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 628-634	6.7	20
375	The elusive pursuit of progress in limited stage small-cell lung cancer. <i>Lancet Oncology</i> , <b>2021</b> , 22, 290-291	21.7	1
374	The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 223-230	5.3	2
373	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 1165-1184	3.6	2
372	Developments in radiation techniques for thoracic malignancies. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	2
371	Age-related treatment patterns for stage I NSCLC in three European countries. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 1214-1219	3.6	1
370	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 860-867	8.9	118
369	Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100172	1.4	
368	Finding the Goldilocks zone in neoadjuvant radioimmunotherapy. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 545-546	19.4	1
367	The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100195	1.4	
366	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , <b>2021</b> , 151, 30-38	5.9	9
365	Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 1176-1184	4	7
364	Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. <i>Oncologist</i> , <b>2021</b> , 26, e306-e315	5.7	9
363	Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2021</b> , 152, 149-156	5.9	2
362	X-change symposium: status and future of modern radiation oncology-from technology to biology. <i>Radiation Oncology</i> , <b>2021</b> , 16, 27	4.2	1
361	Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. <i>ESMO Open</i> , <b>2021</b> , 6, 100244	6	9

360	The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, e79-e80	8.9	1
359	Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases. <i>Physics and Imaging in Radiation Oncology</i> , <b>2021</b> , 20, 1-4	3.1	1
358	Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 163, 14-20	5.3	2
357	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2830-2838	2.2	248
356	Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 107, 270-278	4	28
355	A Primer on Interstitial Lung Disease and Thoracic Radiation. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 902-913	2.3	14
354	Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , <b>2020</b> , 14, 17-23	3.1	26
353	Stereotactic ablative radiotherapy in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease. <i>Acta Oncologica</i> , <b>2020</b> , 59, 569-573	3.2	6
352	Points to consider regarding the SABR-COMET trial - Authors Reply. <i>Lancet, The</i> , <b>2020</b> , 395, e20	4.0	2
351	Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study. <i>Lung Cancer</i> , <b>2020</b> , 141, 89-96	5.9	4
350	Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e84-e88	4.9	18
349	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 146, 223-229	5.3	105
348	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 176-189	8.9	17
347	Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 144, 46-52	5.3	30
346	Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 142, 217-223	5.3	16
345	Testing the Effects of Modality and Narration Style on Patients' Information Use in a Lung Cancer Treatment Decision Aid. <i>Medical Decision Making</i> , <b>2020</b> , 40, 990-1002	2.5	
344	The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
343	Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 152, 26-29	5.3	3

342	Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. <i>Radiation Oncology</i> , <b>2020</b> , 15, 214	4.2	29
341	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 764	4.8	6
340	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 943-947	4	20
339	A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy For Prostate Cancer: Early Toxicity Results. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 1086-1094	4	61
338	End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 141, 200-207	5.3	10
337	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1761-1767	2.5	1
336	Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 933-941	4	40
335	Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. <i>Lancet, The</i> , <b>2019</b> , 393, 2051-2058	40	764
334	A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 459-467	8.9	6
333	Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , <b>2019</b> , 19, 816	4.8	81
332	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 2109-2119	8.9	96
331	Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5cm. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 103, 259-267	4	8
330	Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 132, 16-22	5.3	23
329	Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 488-496	8.9	7
328	Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 233-238	5.3	7
327	Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 689-698	8.9	15
326	Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 186-194		46
325	Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. <i>Practical Radiation Oncology</i> , <b>2018</b> , 8, e71-e78	2.8	26

324	Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 927-934	4	15
323	Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 855-862	8.9	11
322	Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease <b>2018</b> , 342-354.e4		
321	MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 858-866	4	77
320	Patient-reported Outcome Measurements on the Tolerance of Magnetic Resonance Imaging-guided Radiation Therapy. <i>Cureus</i> , <b>2018</b> , 10, e2236	1.2	25
319	Usage of Prophylactic Cranial Irradiation in Elderly Patients With Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e263-e267	4.9	16
318	Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. <i>Clinical Oncology</i> , <b>2018</b> , 30, 17-22	2.8	3
317	Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 642-651	2.2	68
316	Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 426-433	4	43
315	SBRT for pancreatic cancer: In regard of Bohoudi et al. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 511-512	5.3	1
314	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1183-1188	8.9	8
313	Analysis of components of variance determining probability of setup errors in CBCT-guided stereotactic radiotherapy of lung tumors. <i>Medical Physics</i> , <b>2017</b> , 44, 382-388	4.4	4
312	The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1749-1751	2.2	9
311	Radical-Intent Treatment of Lung Cancer after Prior Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e26-e27	8.9	1
310	Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy. <i>Acta Oncologica</i> , <b>2017</b> , 56, 548-554	3.2	8
309	Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. <i>Lung Cancer</i> , <b>2017</b> , 108, 150-153	5.9	44
308	Surgical Treatment of Complications After High-Dose Chemoradiotherapy for Lung Cancer. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 436-442	2.7	6
307	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1183-1209	8.9	29

306	Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1224-1227	10.2	7
305	Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 974-982	8.9	30
304	Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 622-631	4	67
303	SABR Given Thoughtfully. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 766	4	
302	Management of Progressive Pulmonary Nodules Found During and outside of CT Lung Cancer Screening Studies. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1755-1765	8.9	6
301	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 11-17	5.3	149
300	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 1-10	5.3	109
299	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2016</b> , 27, v1-v27	10.3	590
298	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 953-62	2.2	254
297	Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 1121-8	4	95
296	Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 566-72	8.9	22
295	Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, e141-e149	4.9	35
294	Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors Reply. <i>Lancet Oncology</i> , <b>2016</b> , 17, e42-e43	21.7	2
293	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 612-20	4	32
292	Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands. <i>Lung Cancer</i> , <b>2016</b> , 94, 54-60	5.9	1
291	Quantitative assessment of target delineation variability for thymic cancers: Agreement evaluation of a prospective segmentation challenge. <i>Journal of Radiation Oncology</i> , <b>2016</b> , 5, 55-61	0.7	4
290	Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 239-44	4.9	49
289	Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8529-8529	2.2	

288	Can the probability of radiation esophagitis be reduced without compromising lung tumor control: A radiobiological modeling study. <i>Acta Oncologica</i> , <b>2016</b> , 55, 926-30	3.2	2
287	Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer. <i>Cancer</i> , <b>2016</b> , 122, 322-3	6.4	2
286	Treatment recommendations by clinicians in stage I non-small cell lung cancer: A study of factors that influence the likelihood of accounting for the patient's preference. <i>Patient Education and Counseling</i> , <b>2016</b> , 99, 1808-1813	3.1	13
285	Should regional ventilation function be considered during radiation treatment planning to prevent radiation-induced complications?. <i>Medical Physics</i> , <b>2016</b> , 43, 5072	4.4	12
284	Treatment of Stage IIIA Non-Small-Cell Lung Cancer: Charting the Next Steps. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 609-10	3.1	1
283	Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer. <i>Radiation Oncology</i> , <b>2016</b> , 11, 131	4.2	19
282	An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors. <i>Acta Oncologica</i> , <b>2016</b> , 55, 934-7	3.2	5
281	Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1081-9	8.9	116
280	Defining a standard set of patient-centred outcomes for lung cancer. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 852-60	13.6	57
279	A critical review of recent developments in radiotherapy for non-small cell lung cancer. <i>Radiation Oncology</i> , <b>2016</b> , 11, 115	4.2	85
278	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1479-1489	5.4	10
277	Surgery versus SABR for resectable non-small-cell lung cancer - Authors' Reply. <i>Lancet Oncology</i> , <b>2015</b> , 16, e374-5	21.7	8
276	In Reply to Cobben and Jager. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 700-1	4	2
275	Parenchymal lung changes on computed tomography after stereotactic radiotherapy using high dose rate flattening filter free beams. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 114, 357-60	5.3	1
274	Improving radiotherapy planning for large volume lung cancer: a dosimetric comparison between hybrid-IMRT and RapidArc. <i>Acta Oncologica</i> , <b>2015</b> , 54, 427-32	3.2	10
273	Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. <i>Lung Cancer</i> , <b>2015</b> , 87, 283-9	5.9	53
272	Radiotherapy for extensive stage small-cell lung cancer - Authors' Reply. <i>Lancet</i> , <b>2015</b> , 385, 1292-3	4.0	28
271	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 325-33	4.9	55

270	Second primary lung cancers following a diagnosis of primary head and neck cancer. <i>Lung Cancer</i> , <b>2015</b> , 88, 94-9	5.9	19
269	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncology</i> , <b>2015</b> , 16, 630-7	21.7	877
268	High-dose conventional thoracic re-irradiation for lung cancer: updated results. <i>Lung Cancer</i> , <b>2015</b> , 88, 235-6	5.9	9
267	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1573-88	10.3	225
266	Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 64-70	5.3	45
265	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III Non-Small-Cell Lung Cancer: Is There an Impact on Radiation Pneumonitis Rates?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2927	2.2	3
264	Stereotactic body radiotherapy for central lung tumours. <i>British Journal of Radiology</i> , <b>2015</b> , 88, 20150410	9.4	3
263	Diagnostic challenges in survivors of early stage lung cancer. <i>Lung Cancer</i> , <b>2015</b> , 90, 212-6	5.9	3
262	Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2196	10.3	8
261	Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 44-8	5.3	57
260	Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 91, 133-9	4	13
259	Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 114, 138-47	5.3	74
258	Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. <i>Lancet</i> , <b>2015</b> , 385, 36-42	40	320
257	A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. <i>BMC Cancer</i> , <b>2015</b> , 15, 959	4.8	27
256	Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 82-90	4	24
255	Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 115, 361-6	5.3	25
254	Texture analysis of automatic graph cuts segmentations for detection of lung cancer recurrence after stereotactic radiotherapy <b>2015</b> ,		1
253	Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1195-200	8.9	45



252	Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy. <i>Journal of Medical Imaging</i> , <b>2015</b> , 2, 041010	2.6	19
251	Treatment for high-risk patients with early-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 377	2.2	2
250	Markerless tracking of small lung tumors for stereotactic radiotherapy. <i>Medical Physics</i> , <b>2015</b> , 42, 1640-524	4.4	28
249	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 7506-7506	2.2	7
248	Exploring controversies in lung cancer using structured pro-con debates. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 475	4.4	
247	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1462-74	10.3	268
246	Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. <i>Medical Physics</i> , <b>2014</b> , 41, 033502	4.4	73
245	Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 90, 843-9	4	11
244	Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. <i>Lung Cancer</i> , <b>2014</b> , 85, 218-23	5.9	11
243	Computed tomography surveillance of patients with resected lung cancer: Recurrence or second primary lung cancer?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2014</b> , 147, 1715	1.5	
242	An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 346-55	4.9	253
241	High-dose, conventionally fractionated thoracic reirradiation for lung tumors. <i>Lung Cancer</i> , <b>2014</b> , 83, 356-62	5.9	31
240	Comparison of radiation-induced normal lung tissue density changes for patients from multiple institutions receiving conventional or hypofractionated treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 626-32	4	10
239	A brief report on outcomes of stereotactic ablative radiotherapy for a second primary lung cancer: evidence in support of routine CT surveillance. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1222-5	8.9	10
238	Early prediction of lung cancer recurrence after stereotactic radiotherapy using second order texture statistics <b>2014</b> ,		1
237	When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis. <i>Chest</i> , <b>2014</b> , 146, 1021-1028	5.3	49
236	Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010. <i>Acta Oncologica</i> , <b>2014</b> , 53, 316-23	3.2	8
235	Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. <i>Oncologist</i> , <b>2014</b> , 19, 880-5	5.7	21

234	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1475-84	10.3	174
233	Investigating strategies to reduce toxicity in stereotactic ablative radiotherapy for central lung tumors. <i>Acta Oncologica</i> , <b>2014</b> , 53, 330-5	3.2	11
232	The oligometastatic state - separating truth from wishful thinking. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 549-57	19.4	178
231	Communicating cancer treatment information using the Web: utilizing the patient's perspective in website development. <i>BMC Medical Informatics and Decision Making</i> , <b>2014</b> , 14, 116	3.6	9
230	A brief report of 10-year trends in the use of stereotactic lung radiotherapy at a dutch academic medical center. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 114-7	8.9	11
229	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1681-1690	10.3	208
228	Surgery for early-stage lung cancer: post-operative 30-day versus 90-day mortality and patient-centred care. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 675-7	7.5	13
227	Systematic review of fractionated brain metastases radiotherapy. <i>Journal of Radiation Oncology</i> , <b>2014</b> , 3, 29-41	0.7	9
226	Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumors. <i>Strahlentherapie Und Onkologie</i> , <b>2014</b> , 190, 204-9	4.3	4
225	New techniques for assessing response after hypofractionated radiotherapy for lung cancer. <i>Journal of Thoracic Disease</i> , <b>2014</b> , 6, 375-86	2.6	14
224	Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7502-7502	2.2	
223	When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7534-7534	2.2	
222	Systematic review of brain metastases prognostic indices. <i>Practical Radiation Oncology</i> , <b>2013</b> , 3, 101-6	2.8	13
221	Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 95-9	5.3	45
220	Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 107, 403-8	5.3	29
219	Propensity-score matched pair comparison of whole brain with simultaneous in-field boost radiotherapy and stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 206-9	5.3	14
218	Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2013</b> , 80, 62-7	5.9	14
217	Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 690-6	4	120

216	Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. <i>Acta Oncologica</i> , <b>2013</b> , 52, 910-8	3.2	40
215	Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocol. <i>European Journal of Surgical Oncology</i> , <b>2013</b> , 39, 197-203	3.6	16
214	A statistical comparison of prognostic index systems for brain metastases after stereotactic radiosurgery or fractionated stereotactic radiation therapy. <i>Clinical Oncology</i> , <b>2013</b> , 25, 227-35	2.8	12
213	Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e270-4	21.7	60
212	High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 51-7	5.3	96
211	Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 85, 444-50	4	384
210	Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: in response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. <i>Oral Oncol</i> 2012;48(9):905-11. <i>Oral Oncology</i> , <b>2013</b> , 49, e8	4.4	2
209	What causes early mortality in patients with large tumors receiving radical chemo-radiotherapy for non-small cell lung cancer? In response to Ball et al. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 179-80	5.3	
208	Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 77-81	5.3	22
207	Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. <i>Lung Cancer</i> , <b>2013</b> , 82, 95-102	5.9	123
206	Dosimetric impact of intrafraction motion during RapidArc stereotactic vertebral radiation therapy using flattened and flattening filter-free beams. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 86, 420-5	4	21
205	Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 276-82	5.3	190
204	Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 1-5	4.9	26
203	Comparing rigid and deformable dose registration for high dose thoracic re-irradiation. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 323-6	5.3	18
202	CT image feature analysis in distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a preliminary study <b>2013</b> ,		1
201	Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer. <i>Acta Oncologica</i> , <b>2013</b> , 52, 676-8	3.2	2
200	Bowel-sparing intensity-modulated radiotherapy (IMRT) for palliation of large-volume pelvic bone metastases: rationale, technique and clinical implementation. <i>Acta Oncologica</i> , <b>2013</b> , 52, 877-80	3.2	3
199	Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1543-8	10.3	192

198	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2013</b> , 24 Suppl 6, vi89-98	10.3	376
197	Digital tomosynthesis (DTS) for verification of target position in early stage lung cancer patients. <i>Medical Physics</i> , <b>2013</b> , 40, 091904	4.4	13
196	Surveillance with computed tomography after curative treatment of early-stage lung cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3607	2.2	2
195	Pulmonary atelectasis after stereotactic ablative radiotherapy for a central lung tumor. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e94-5	8.9	6
194	Are the reported clinical outcomes with stereotactic ablative radiotherapy generalizable?. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 995-6	8.9	
193	Blinded assessment of radiological changes after stereotactic ablative radiotherapy (SABR) for early-stage lung cancer: Local recurrences versus fibrosis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7520-7520	2.2	2
192	Complication probability for radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT). <i>Journal of Radiosurgery and SBRT</i> , <b>2013</b> , 2, 99-104	0.4	1
191	Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes. <i>Journal of Thoracic Disease</i> , <b>2013</b> , 5, 116-22	2.6	21
190	Curative Radiotherapy in Patients Inoperable for Medical Reasons <b>2013</b> , 151-162		
189	4-Dimensional Imaging for Radiation Oncology: A Clinical Perspective <b>2013</b> , 251-284		
188	Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1148-54	8.9	81
187	Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 1149-56	4	135
186	Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 348-53	4	261
185	Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer: in regards to Register et al. <i>Int J Radiat Oncol Biol Phys</i> 2011;80:1015-1022. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 492, author reply 492	4	2
184	Fast arc delivery for stereotactic body radiotherapy of vertebral and lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, e137-43	4	62
183	Clinical application of a novel hybrid intensity-modulated radiotherapy technique for stage III lung cancer and dosimetric comparison with four other techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, e297-303	4	34
182	In reply to Zagar and Marks. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 84, 305-6	4	2
181	Feasibility of using anatomical surrogates for predicting the position of lung tumours. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 287-9	5.3	6

180	Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 335-42	5.3	154
179	An analysis of patient positioning during stereotactic lung radiotherapy performed without rigid external immobilization. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 28-32	5.3	30
178	Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , <b>2012</b> , 12, 305	4.8	118
177	Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 802-9	21.7	323
176	Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography. <i>Clinical Oncology</i> , <b>2012</b> , 24, e71-80	2.8	25
175	Reflections on the 14th World Conference on Lung Cancer: A European Perspective. <i>Oncologist</i> , <b>2012</b> , 17, 463-465	5.7	
174	Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e104-8	2.2	46
173	Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2743-2747	10.3	111
172	Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1271-5	8.9	22
171	Treatment of peripheral lung tumors arising after a prior pneumonectomy. <i>Chest</i> , <b>2012</b> , 142, 263	5.3	
170	Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7009-7009	2.2	4
169	Imaging for high-precision thoracic radiotherapy. <i>Journal of Thoracic Disease</i> , <b>2012</b> , 4, 106-8	2.6	
168	An evaluation of websites providing patient information on stereotactic body radiation therapy (SBRT) for stage I lung cancer in three Western European countries. <i>Journal of Radiosurgery and SBRT</i> , <b>2012</b> , 1, 303-315	0.4	
167	Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer. <i>Lung Cancer</i> , <b>2011</b> , 74, 451-6	5.9	26
166	Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 763-72	21.7	489
165	The MARS feasibility trial: conclusions not supported by data [AuthorsReply]. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1094-1095	21.7	24
164	Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 101, 250-4	5.3	99
163	Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 161-5	5.3	40

162	Use of megavoltage cine-images for studying intra-thoracic motion during radiotherapy for locally advanced lung cancer. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 155-60	5.3	9
161	Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 101, 240-4	5.3	126
160	Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 974-8	4	76
159	Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 1442-57	4	216
158	Imaging for stereotactic spine radiotherapy: clinical considerations. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 321-30	4	27
157	Four-dimensional Radiation Therapy for Non-Small Cell Lung Cancer: A Clinical Perspective. <i>Medical Radiology</i> , <b>2011</b> , 157-172	0.2	
156	Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , <b>2011</b> , 23, 133-9	4.2	42
155	Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 2036-43	8.9	186
154	Radiological changes after stereotactic radiotherapy for stage I lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1221-8	8.9	113
153	Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 2052-7	8.9	77
152	Stereotactic lung radiotherapy: do we need fiducial markers?. <i>Annals of Thoracic Surgery</i> , <b>2011</b> , 91, 335-6; author reply 336	2.7	4
151	Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy. <i>Radiation Oncology</i> , <b>2011</b> , 6, 74	4.2	19
150	Time for reappraisal of extracranial treatment options? Synchronous brain metastases from nonsmall cell lung cancer. <i>Cancer</i> , <b>2011</b> , 117, 597-605	6.4	16
149	RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 429-35	4	69
148	Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 506-13	4	53
147	Dosimetric impact of interplay effect on RapidArc lung stereotactic treatment delivery. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 305-11	4	85
146	Quality assurance of 4D-CT scan techniques in multicenter phase III trial of surgery versus stereotactic radiotherapy (radiosurgery or surgery for operable early stage (stage 1A) non-small-cell lung cancer [ROSEL] study). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 918-27	4	53
145	Radiotherapy in small-cell lung cancer: lessons learned and future directions. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 998-1003	4	25

144	Impact of the calculation resolution of AAA for small fields and RapidArc treatment plans. <i>Medical Physics</i> , <b>2011</b> , 38, 4471-9	4.4	36
143	Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning. <i>British Journal of Radiology</i> , <b>2011</b> , 84, 919-29	3.4	8
142	Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. <i>Annals of Oncology</i> , <b>2011</b> , 22, 132-138	10.3	35
141	A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 553-558	10.3	29
140	A new approach to quantifying lung damage after stereotactic body radiation therapy. <i>Acta Oncologica</i> , <b>2011</b> , 50, 509-17	3.2	38
139	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). <i>Annals of Oncology</i> , <b>2011</b> , 22, 1154-1163	10.3	134
138	Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies. <i>Journal of Thoracic Disease</i> , <b>2011</b> , 3, 189-96	2.6	51
137	The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. <i>Cancer Research and Treatment</i> , <b>2011</b> , 43, 75-82	5.2	26
136	Radiation oncology: overview and recent advances. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , <b>2010</b> , 40, 136-43; quiz 143-4	0.9	2
135	Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5153-9	2.2	349
134	Stage I non-small cell lung cancer (NSCLC) in patients aged 75 years and older: does age determine survival after radical treatment?. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 818-24	8.9	40
133	European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5301-10	2.2	189
132	Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies. <i>Lung Cancer</i> , <b>2010</b> , 69, 302-6	5.9	11
131	Stereotactic radiotherapy for stage I lung cancer: current results and new developments. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , <b>2010</b> , 14, 115-8	1.3	19
130	New developments in arc radiation therapy: a review. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36, 393-9	14.4	91
129	Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: a planning study and early clinical data. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 94, 224-8	5.3	62
128	Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 96, 67-72	5.3	53
127	A novel simple approach for incorporation of respiratory motion in stereotactic treatments of lung tumors. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 443-8	5.3	10

126	Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 437-42	5.3	168
125	Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 431-6	5.3	111
124	Volumetric modulated arc therapy for advanced pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , <b>2010</b> , 186, 382-7	4.3	33
123	Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 1106-13	4	69
122	Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. <i>Cancer</i> , <b>2010</b> , 116, 406-14	6.4	149
121	In Reply to Dr. Bauman. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 78, 965	4	
120	Inferring positions of tumor and nodes in Stage III lung cancer from multiple anatomical surrogates using four-dimensional computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 77, 1553-60	4	8
119	Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study. <i>Anticancer Research</i> , <b>2010</b> , 30, 4237-43	2.3	6
118	Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2009</b> , 36, 1052-7	3	7
117	Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 78-84	2.2	201
116	PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10, 193-8	4.9	47
115	Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. <i>Cancer</i> , <b>2009</b> , 115, 587-94	6.4	49
114	Volumetric modulated arc radiotherapy for vestibular schwannomas. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 610-5	4	75
113	Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. <i>Radiation Oncology</i> , <b>2009</b> , 4, 1	4.2	203
112	Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 1092-9	4	50
111	Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 1391-6	4	56
110	Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1092-7	4	23
109	Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 252-9	4	340



108	An evaluation of two internal surrogates for determining the three-dimensional position of peripheral lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 623-9	4	10
107	Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 253-9	4	85
106	Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable Stage I-II non-small-cell lung cancer. In reply to Dr. Xiao et al. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 318; author reply 318	4	2
105	Comments on Single-Arc IMRT? <i>Physics in Medicine and Biology</i> , <b>2009</b> , 54, L31-4; author reply L35-6	3.8	24
104	Radiotherapy for lung cancer: clinical impact of recent technical advances. <i>Lung Cancer</i> , <b>2009</b> , 64, 1-8	5.9	37
103	Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 93, 122-4	5.3	130
102	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. <i>Lancet Oncology</i> , <b>2009</b> , 10, 467-74	21.7	247
101	Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 87, 59-64	5.3	24
100	Novel tools in radiotherapy. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 7, vii294-9	10.3	2
99	Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. <i>Oncologist</i> , <b>2008</b> , 13, 309-19	5.7	43
98	CT-guided pulmonary radiofrequency ablation. <i>Radiology</i> , <b>2008</b> , 246, 334-5; author reply 334-5	20.5	
97	Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1050-3	8.9	19
96	Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 1215-20	4	36
95	Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 70, 685-92	4	438
94	Analysis of carina position as surrogate marker for delivering phase-gated radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 1111-7	4	23
93	Impact of audio-coaching on the position of lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 1118-23	4	33
92	Color Intensity Projections: A Simple Way to Display Changes in Astronomical Images. <i>Publications of the Astronomical Society of the Pacific</i> , <b>2007</b> , 119, 523-526	5	1
91	Prophylactic cranial irradiation in extensive small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 664-72	59.2	793

90	B5-06: Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S349-S350	8.9	3
89	B5-04: Clinical results and toxicity after 4-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S348	8.9	4
88	Staging nodal disease in non-small cell lung cancer: implications for radiation therapy. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 585-7	8.9	4
87	Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 775-80	4	91
86	Is adaptive treatment planning required for stereotactic radiotherapy of stage I non-small-cell lung cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 1370-4	4	48
85	A four-dimensional CT-based evaluation of techniques for gastric irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, 903-9	4	34
84	Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. <i>Radiation Oncology</i> , <b>2007</b> , 2, 2	4.2	26
83	Verifying 4D gated radiotherapy using time-integrated electronic portal imaging: a phantom and clinical study. <i>Radiation Oncology</i> , <b>2007</b> , 2, 32	4.2	12
82	Reply: Patterns of nodal recurrence after omission of elective nodal irradiation for limited-stage small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 276-276	8.7	9
81	Lung cancer: intensity-modulated radiation therapy, four-dimensional imaging and mobility management. <i>Frontiers of Radiation Therapy and Oncology</i> , <b>2007</b> , 40, 239-252		7
80	Design of clinical trials of radiation combined with antiangiogenic therapy. <i>Oncologist</i> , <b>2007</b> , 12, 465-77	5.7	78
79	Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, e10-1	2.2	47
78	Residual disease at the bronchial stump after curative resection for lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2007</b> , 32, 29-34	3	57
77	Stereotactic radiotherapy for centrally located early-stage lung tumors. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 464; author reply 465	2.2	11
76	PL3-02: Advances in radiation oncology. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S146-S148	8.9	
75	Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 912-5	8.9	26
74	Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 1138-9	8.9	6
73	Can mediastinal nodal mobility explain the low yield rates for transbronchial needle aspiration without real-time imaging?. <i>Chest</i> , <b>2007</b> , 131, 1783-7	5.3	30

72	Involved-node radiotherapy to the mediastinum. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 82, 108-9; author reply 109-10	5.3	9
71	A1-02: A need to standardize post-operative radiotherapy (PORT) fields used for non-small cell lung cancer (NSCLC): analysis of an international dummy-run study. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S308-S309	8.9	2
70	Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 625-30	8.7	67
69	4D imaging for target definition in stereotactic radiotherapy for lung cancer. <i>Acta Oncologica</i> , <b>2006</b> , 45, 966-72	3.2	64
68	Evaluating mobility for radiotherapy planning of lung tumors: a comparison of virtual fluoroscopy and 4DCT. <i>Lung Cancer</i> , <b>2006</b> , 53, 31-7	5.9	24
67	Reproducibility of target volumes generated using uncoached 4-dimensional CT scans for peripheral lung cancer. <i>Radiation Oncology</i> , <b>2006</b> , 1, 43	4.2	26
66	A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. <i>Radiation Oncology</i> , <b>2006</b> , 1, 8	4.2	45
65	Renal mobility during uncoached quiet respiration: an analysis of 4DCT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 799-803	4	48
64	Time trends in target volumes for stage I non-small-cell lung cancer after stereotactic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 1221-8	4	55
63	Color intensity projections: a rapid approach for evaluating four-dimensional CT scans in treatment planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 954-61	4	26
62	A Phase II Study of Induction Therapy with Carboplatin and Gemcitabine among Patients with Locally Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 532-536	8.9	7
61	Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 62, 554-60	4	169
60	Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 63, 334-9	4	17
59	Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 63, 253-60	4	238
58	Critical review of PET-CT for radiotherapy planning in lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 56, 345-51	7	36
57	The role of radiotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16 Suppl 2, ii223-8	10.3	11
56	Target Volumes in Non-Small Cell Lung Cancer <b>2005</b> , 97-110		
55	Anatomical and Biological Imaging <b>2005</b> , 109-130		

54	Defining target volumes for non-small cell lung carcinoma. <i>Seminars in Radiation Oncology</i> , <b>2004</b> , 14, 308-14	5.5	34
53	Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 1283-90	4	248
52	A treatment planning study evaluating a simultaneous integrated boost technique for accelerated radiotherapy of stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2004</b> , 45, 57-65	5.9	10
51	Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2004</b> , 45 Suppl 1, S93-6	5.9	7
50	Reply to "Radiation pneumonitis and docetaxel". <i>Lung Cancer</i> , <b>2004</b> , 43, 117-8; author reply 119-20	5.9	
49	Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 71, 139-46	5.3	179
48	Indications and limitations of radiotherapy in malignant pleural mesothelioma. <i>Current Opinion in Oncology</i> , <b>2003</b> , 15, 144-7	4.2	19
47	Procedures for high precision setup verification and correction of lung cancer patients using CT-simulation and digitally reconstructed radiographs (DRR). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 55, 804-10	4	23
46	In regard to Rosenman et al., high-dose conformal radiotherapy for treatment of stage III A/B non-small-cell lung cancer: technical issues and results of a phase I/II trial. <i>IJROBP</i> 2002;54:348-356. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 55, 1458-9; author reply 1459-60	4	
45	Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 56, 348-54	4	106
44	Are multiple CT scans required for planning curative radiotherapy in lung tumors of the lower lobe?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 55, 1394-9	4	67
43	Critical factors for patient management. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S7-8	5.9	1
42	Induction treatment before surgery for non-small cell lung cancer. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S9-14	5.9	63
41	What margins are necessary for incorporating mediastinal nodal mobility into involved-field radiotherapy for lung cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 53, 1211-5	4.5	25
40	Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 54, 999-1006	4	85
39	Incorporating lung tumor mobility in radiotherapy planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 52, 1142-3; author reply 1144	4	3
38	Curative radiotherapy for a second primary lung cancer arising after pneumonectomy -- techniques and results. <i>Radiotherapy and Oncology</i> , <b>2002</b> , 62, 21-5	5.3	14
37	Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?. <i>Radiotherapy and Oncology</i> , <b>2002</b> , 63, 151-7	5.3	76

36	Can errors in reconstructing pre-chemotherapy target volumes contribute to the inferiority of sequential chemoradiation in stage III non-small cell lung cancer (NSCLC)?. <i>Lung Cancer</i> , <b>2002</b> , 38, 297-301	5.9	14
35	Analysis and reduction of 3D systematic and random setup errors during the simulation and treatment of lung cancer patients with CT-based external beam radiotherapy dose planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 49, 857-68	4	105
34	Multiple "slow" CT scans for incorporating lung tumor mobility in radiotherapy planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 51, 932-7	4	167
33	Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer--an analysis of data generated using GlowCT scans. <i>Radiotherapy and Oncology</i> , <b>2001</b> , 61, 93-9	5.3	48
32	Predictive factors in radiotherapy for non-small cell lung cancer: present status. <i>Lung Cancer</i> , <b>2001</b> , 31, 43-56	5.9	81
31	An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2001</b> , 32, 145-53	5.9	22
30	Regarding scoring of radiation pneumonitis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2000</b> , 48, 609	4	1
29	Mucosal dose prescription in endobronchial brachytherapy: a study based on CT-dosimetry. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2000</b> , 46, 1051-9	4	6
28	A CT-assisted method of dosimetry in brachytherapy of lung cancer. Rotterdam Oncological Thoracic Study Group. <i>Radiotherapy and Oncology</i> , <b>2000</b> , 55, 75-80	5.3	12
27	Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 43, 511-6	4	89
26	An analysis of anatomic landmark mobility and setup deviations in radiotherapy for lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 43, 827-32	4	48
25	Beam intensity modulation for penumbra enhancement in the treatment of lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 44, 449-54	4	15
24	Brachytherapy for recurrent head and neck cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>1999</b> , 13, 531-42	3.1	13
23	A simplified CT-based definition of the lymph node levels in the node negative neck. <i>Radiotherapy and Oncology</i> , <b>1999</b> , 52, 35-42	5.3	78
22	Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>1999</b> , 53, 247-55	5.3	124
21	Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1997</b> , 40, 1-10	3.5	35
20	Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1997</b> , 38, 497-506	4	81
19	The history of radiotherapy in The Netherlands. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1996</b> , 35, 615-22	4	3

18	Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1995</b> , 31, 209-10	4	4
17	Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1995</b> , 36, 266-70	3.5	5
16	Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1994</b> , 29, 379-82	4	45
15	The radiobiological basis of concomitant cisplatin and radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1993</b> , 27, 483-4	4	1
14	Letter in response to paper by Abratt et al., <i>Cancer Chemother Pharmacol</i> (1992) 30: 495. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1993</b> , 31, 500-1	3.5	
13	The interaction of cisplatin and radiotherapy. <i>Clinical Oncology</i> , <b>1993</b> , 5, 191-2	2.8	0
12	Diagnosis and treatment of lymphomatoid granulomatosis. <i>Postgraduate Medical Journal</i> , <b>1992</b> , 68, 841-2		
11	The diagnosis and treatment of nasal lymphoma, an important cause of upper respiratory tract destruction. <i>Clinical Otolaryngology</i> , <b>1992</b> , 17, 563-6	1.8	4
10	Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 2084	7.5	9
9	Overcoming tumour radiation resistance resulting from acute hypoxia. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 2085-6	7.5	1
8	Failure of palliative radiotherapy in high-grade angiosarcoma of bone. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1934	7.5	1
7	Palliation of malignant pheochromocytoma with combination chemotherapy. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1006-7	7.5	7
6	Primary intracranial germ cell tumours (GCT) fail to highlight important aspects of the current management of this condition. <i>Journal of Neuro-Oncology</i> , <b>1992</b> , 14, 289-90	4.8	
5	Nasal peripheral T-cell lymphoma: a 20-year review of cases treated in Scotland. <i>Clinical Oncology</i> , <b>1992</b> , 4, 96-100	2.8	14
4	Lung abscess: a fatal complication of treatment for testicular teratoma. <i>Clinical Oncology</i> , <b>1991</b> , 3, 345-7	2.8	1
3	Optimum management of pineal germ cell tumours. <i>Clinical Oncology</i> , <b>1991</b> , 3, 301	2.8	
2	Malignant pineal teratomas: a report on three patients and the case for craniospinal irradiation following chemotherapy. <i>Radiotherapy and Oncology</i> , <b>1991</b> , 22, 209-12	5.3	21
1	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial		13

